Evaluating Novel Targets & GLP-1 Combination Therapies to Improve Body Composition, Tolerability, & Longer Lasting Clinical Outcomes
The Obesity Drug Development Summit Europe is set to be the leading industry-focused event for advancing next-generation obesity therapies. Taking place in Barcelona, Spain, from the 1st to 2nd of October 2025, this inaugural summit will bring together over 50 leaders from pharma, biotech, and academia. Attendees will address critical challenges in obesity care, including lean mass preservation, patient stratification, scalable manufacturing, and payer-driven endpoints.
This event offers a unique opportunity to explore cutting-edge therapies such as GIPR modulators, DNA-encoded treatments, and RNA-based therapies, which aim to achieve metabolic transformation beyond simple weight loss. Participants will gain insights into designing clinical trials that align with payer expectations by leveraging real-world evidence and precision biomarkers, with contributions from industry leaders like Novo Nordisk. The summit will also delve into optimising combination therapies, including GLP-1-based regimens with myostatin inhibitors and amylin analogues, to enhance efficacy and muscle preservation.
With innovations in oral formulations and long-acting injectables from companies like Ambrosia Biosciences and Cytoki Pharma, manufacturing challenges will be addressed head-on. As the obesity therapeutics market evolves rapidly, this summit is a vital platform to collaborate, benchmark, and shape the future of obesity care through precision medicine and sustainable drug development.
The sessions were amazing and there was a very good opportunity to discuss and meet with all of the meeting participants.
Attendee, Obesity Event Series, Calorify
Broad perspective on the future of obesity treatments from both scientific presenters and service providers.
Attendee, Obesity Event Series, Adipo Therapeutics
High quality attendance, great selection of sponsor and vendor selection, high quality scientific talks.
Attendee, Obesity Event Series, Remalda
Explore the Full Event Guide
- 50+ industry leaders from top pharma, biotech, and academic organisations.
- 17+ expert speakers covering cutting-edge topics.
- 2 days of content featuring deep dives and case studies.
- Tailored networking opportunities to connect with key decision-makers.
- 5 core themes across the obesity drug R&D cycle: from next-gen therapies, to regulation.
Official Partners
Attending Companies Include
Explore Related Events
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive regulatory insights during our packed agenda, interactive roundtables, and new CXOs’ panel discussion.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.